UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1928, 2022 (July 1522, 2022)

LEAD EDGE GROWTH OPPORTUNITIES, LTD

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40270		98-1573983
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

96 Spring Street, 5th Floor

New York, New York

10012

(Address of principal executive offices)

(Zip Code)

(212) 984-2421
Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-fourth of one redeemable Warrant	LEGAU	Nasdaq Capital Market

Class A Ordinary Shares included as part of the units	LEGA	Nasdaq Capital Market

Warrants included as part of the Units, each whole Warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50	LEGAW	Nasdaq Capital Market

☒

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 53.0201. ~~Departure~~Notice of ~~Directors~~Delisting or ~~Principal~~Failure ~~Officers;~~to ~~Election~~Satisfy ofa ~~Directors~~Continued Listing Rule or Standard; ~~Appointment~~Transfer of ~~Principal Officers~~Listing.

On July 1522, 2022, ~~Margaret~~Nasdaq C.Listing ~~Whitman~~Qualifications ~~resigned~~Department as(“Nasdaq”) ~~member~~notified ofLead ~~the~~Edge ~~Board~~Growth ofOpportunities, ~~Directors~~Ltd (the “~~Board~~Company”) ofthat the ~~Lead~~Company ~~Edge~~no ~~Growth~~longer ~~Opportunities,~~complies ~~Ltd~~with Nasdaq’s independent director requirements as set forth in Listing Rule 5605. The staff of Nasdaq (the “~~Company~~Staff”) ~~following~~ ~~her~~determined ~~public~~that ~~office~~the ~~confirmation~~Company’s bynon-compliance was due to the Uresignation of Ms.S Margaret C. ~~Senate~~Whitman from the Company’s Board of Directors (the “Board”) as of July 15, 2022. The Staff determined that it is necessary and appropriate for the ~~Ambassador~~protection of the investors to ~~Kenya~~disclose potential delisting proceedings due to non-compliance.

~~Ms.~~Pursuant ~~Whitman~~to ~~served~~Listing asRule an5605(b)(1)(A), ~~independent~~the ~~director~~Staff ofhas provided the Company ~~and~~a cure period in order to regain compliance as ~~the~~follows: ~~chairperson~~(a) ~~member~~until the earlier of the Company’s ~~Nominating~~next ~~Committee~~annual ofshareholders’ meeting or July 15, 2023; or (b) if the ~~Board~~next annual shareholders’ meeting is held before January 11, 2023, then the Company must evidence compliance no later than January 11, 2023 (the “~~Nominating Committee~~Cure Period”). ~~Ms.~~The Company ~~Whitman’s~~must ~~resignations~~submit ~~did~~to ~~not~~Nasdaq ~~result~~documentation, ~~from~~including biographies of any ~~disagreements~~new directors, evidencing compliance with the rules no later than this date. In the event the Company ondoes ~~any~~not ~~matter~~regain ~~relating~~compliance toby ~~its operations,~~this ~~policies~~date, orNasdaq ~~practices.~~rules ~~The~~require ~~size~~Staff ofto ~~the~~provide ~~Board~~written isnotification to ~~now~~the ~~six~~Company ~~(6)~~that ~~following~~its ~~Ms.~~securities ~~Whitman’s~~will ~~departure~~be delisted.

1The Company intends to submit required documentation to Nasdaq within the Cure Period to regain compliance with the Independent Director requirements under the Nasdaq Listing Rules.

~~SIGNATURE~~1

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURE

~~Dated:~~Pursuant ~~July~~to 19the requirements of the Securities Exchange Act of 1934, ~~2022~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~LEAD~~Dated: ~~EDGE~~July ~~GROWTH OPPORTUNITIES~~28, ~~LTD By: /s/ Nimay Mehta Name: Nimay Mehta Title: Chief Financial Officer~~2022

2LEAD EDGE GROWTH OPPORTUNITIES, LTD By: /s/ Nimay Mehta Name: Nimay Mehta Title: Chief Financial Officer

Filing Compare · Lead Edge Growth Opportunities, Ltd